Botulinum toxin type B for treatment of axillar hyperhidrosis

被引:64
作者
Dressler, D
Saberi, FA
Benecke, R
机构
[1] Univ Rostock, Dept Neurol, D-18147 Rostock, Germany
[2] Klinikum Nord, Botulinum Toxin Clin, Dept Neurol, Hamburg, Germany
关键词
botulinum toxin type B; therapy; axillar hyperhydrosis; conversion factor;
D O I
10.1007/s00415-002-0929-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recently, botulinum toxin type B (BT-B) became commercially available for treatment of cervical dystonia. It is the aim of this study to explore its use for treatment of bilateral axillar hyper-hydrosis (HH). For this we directly compared the antihyperhydrotic effect of BTB (NeuroBloc(R)/MyoBloc(TM)) with that of botulinum toxin type A (BT-A) (Botox(R)). 9 patients (HD group) received BT-A 100MU unilaterally and BT-B 4000MU contralaterally. 10 patients (LD group) received BT-A 100MU and BT-B 2000MU All patients were blinded as to which preparation was used in which side. All patients except one reported excellent HH improvement in both axillae. None of the patients had residual HH on clinical examination. The duration of HH improvement until first recurrence in the HD group was 16.0 +/- 4.3 weeks in the BT-A treated axillar and 16.4 +/- 4.5 weeks in the BT-B treated axillae (Wilcoxon rank-sum test, p = 0.336). In the LD group it was 16.4 +/- 5.3 weeks in the BT-B treated axillae and 17.1 +/- 5.7 weeks in the BT-A treated axillae (Wilcoxon rank-sum test, p = 0.059). There was also no difference in the duration of HH improvement between the axillae treated with BT-B 4000MU and BT-B 2000MU (Wilcoxon rank-sum test, p = 0.712). 5 out of 9 patients in the HD group (chi-square test, p = 0.025) and 7 out of 10 patients in the LD group (chi-square test, p = 0.008) reported more application discomfort in the BT-B treated axillae. In 6 out of 9 patients in the HD group (chi-square test, p = 0.014) and in 6 out of 10 patients in the LD group (chi-square test, p = 0.014) the onset of HH improvement appeared earlier in the BT-B treated axillae. One patient in the HD group reported dryness of the mouth and eyes and accomodation difficulties. BT-B is a safe and efficient treatment for axillar HH. Doses of BT-B 2000MU per axilla seem sufficient indicating a conversion factor between BT-A and BT-B in the order of 1:20. With a conversion factor for cervical dystonia in the order of 1:40 the autonomic nervous system seems to be relatively more sensitive to BT-B than to BT-A compared with the motor system.
引用
收藏
页码:1729 / 1732
页数:4
相关论文
共 50 条
  • [41] Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin
    Eriksson Mirkovic, Sandra
    Rystedt, Alma
    Balling, Mie
    Swartling, Carl
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 (01) : 103 - 107
  • [42] Botulinum toxin type B: Opportunities and limitations of its clinical application
    Dressler, D
    Benecke, R
    KLINISCHE NEUROPHYSIOLOGIE, 2001, 32 (04) : 240 - 243
  • [43] Botulinum toxin for the treatment of bruxism
    Tinastepe, Neslihan
    Kucuk, Burcu Bal
    Oral, Koray
    CRANIO-THE JOURNAL OF CRANIOMANDIBULAR & SLEEP PRACTICE, 2015, 33 (04): : 292 - 299
  • [44] Botulinum toxin for treatment of dystonia
    Dressler, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 88 - 96
  • [45] First clinical experience with botulinum toxin type B [Erste erfahrungen mit der klinischen anwendung von botulinum-toxin typ B]
    Dressler D.
    Benecke R.
    Der Nervenarzt, 2002, 73 (2) : 194 - 198
  • [46] Immunogenicity and Long-Term Efficacy of Botulinum Toxin Type B in the Treatment of Cervical Dystonia: Report of 4 Prospective, Multicenter Trials
    Chinnapongse, Robert B.
    Lew, Mark F.
    Ferreira, Joaquim J.
    Gullo, Kristen L.
    Nemeth, Paul R.
    Zhang, Yuxin
    CLINICAL NEUROPHARMACOLOGY, 2012, 35 (05) : 215 - 223
  • [47] Treatment of pathological muscular overcontractions with local injections of botulinum toxin type A
    Erbguth, F
    Claus, D
    NERVENHEILKUNDE, 1996, 15 (04) : 230 - 237
  • [48] Treatment of allergic rhinitis with intranasal infusion of botulinum toxin type A in mice
    Aoishi, Kunihide
    Takahashi, Hirotaka
    Hato, Naohito
    Gyo, Kiyofumi
    Yokota, Makoto
    Ozaki, Shinya
    Suzuki, Motohiko
    LIFE SCIENCES, 2016, 147 : 132 - 136
  • [49] Mouse diaphragm assay for detection of antibodies against botulinum toxin type B
    Dressler, D
    Lange, M
    Bigalke, H
    MOVEMENT DISORDERS, 2005, 20 (12) : 1617 - 1619
  • [50] Comparative electrophysiological study of response to botulinum toxin type B in Japanese and Caucasians
    Arimura, Kimiyoshi
    Arimura, Yumiko
    Takata, Yoshiharu
    Nakamura, Tomonori
    Kaji, Ryuji
    MOVEMENT DISORDERS, 2008, 23 (02) : 240 - 245